Privia Health Group, Inc. (NASDAQ: PRVA) is a Healthcare company in the Medical - Healthcare Information Services industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 139.94 | EPS (ttm) | 0.17 | Insider Own | - | Shs Outstand | 126.01M | Perf Week | -4.19% |
| Market Cap | 3.00B | Forward P/E | 58.58 | EPS next Y | 0.41 | Insider Trans | -0.68% | Shs Float | 113.23M | Perf Month | -12.50% |
| Enterprise Value | 2.58B | PEG | 3.72 | EPS next Q | - | Inst Own | - | Short Float | 3.26% | Perf Quarter | -1.86% |
| Income | 22.00M | P/S | 1.33 | EPS this Y | 43.82% | Inst Trans | - | Short Ratio | 3.46 | Perf Half Y | 1.62% |
| Sales | 2.25B | P/B | 3.72 | EPS next Y | 66.11% | ROA | 1.53% | Short Interest | 3.69M | Perf YTD | 0.34% |
| Book/sh | 6.40 | P/C | 7.14 | EPS next 5Y | 37.61% | ROE | 3.02% | 52W High | 28.82 -17.45% | Perf Year | 26.14% |
| Cash/sh | 3.33 | P/FCF | 21.81 | EPS past 3/5Y | - -9.71% | ROIC | 2.70% | 52W Low | 18.92 25.74% | Perf 3Y | -11.82% |
| Dividend Est. | - | EV/EBITDA | 46.16 | Sales past 3/5Y | 16.09% 21.04% | Gross Margin | 9.59% | Volatility | 2.54% 3.28% | Perf 5Y | -45.65% |
| Dividend TTM | - | EV/Sales | 1.15 | EPS Y/Y TTM | 54.55% | Oper. Margin | 1.62% | ATR (14) | 0.83 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.61 | Sales Y/Y TTM | 29.38% | Profit Margin | 0.97% | RSI (14) | 36.16 | Recom | 2.09 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.61 | EPS Q/Q | - | SMA20 | -8.10% | Beta | 0.88 | Target Price | 29.50 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | 25.83% | SMA50 | -2.66% | Rel Volume | 1.00 | Prev Close | 23.79 |
| Employees | 1,226 | LT Debt/Eq | 0.01 | Earnings | Aug 06 | SMA200 | 0.66% | Avg Volume | 1.12M | Price | 23.79 |
| IPO Date | Apr 28, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -73.30% 7.64% | Net Debt/EBITDA | -7.28 | Volume | 1,125,910 | Change | 0.00% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-26-26 | Reiterated | Barclays | Equal Weight | $22 → $24 |
| Apr-08-26 | Reiterated | Evercore ISI Group | Outperform | $22 → $26 |
| Feb-26-26 | Reiterated | Jefferies | $32 | |
| Feb-26-26 | Reiterated | Piper Sandler | Overweight | $40 → $36 |
| Jan-09-26 | Resumed | RBC Capital | Outperform | $31 |
| Jan-06-26 | Reiterated | Wolfe Research | $31 | |
| Nov-12-25 | Reiterated | Canaccord Genuity | Buy | $30 → $34 |
| Oct-09-25 | Reiterated | Barclays | Equal Weight | $19 → $22 |
| Aug-29-25 | Reiterated | JMP Securities | Market Outperform | $29 → $30 |
| Apr-15-25 | Reiterated | Robert W. Baird | $24 → $26 |
Privia Health Group, Inc. functions as a national entity focused on empowering physicians throughout the United States. It partners with medical groups, health plans, and health systems, with the primary objective of optimizing physician practices, enhancing patient experiences, and appropriately compensating clinicians for care delivered both virtually and in person. To achieve this, Privia offers a comprehensive suite of services. These include technology and population health tools designed to streamline independent providers' workflows; a Management Services Organization (MSO) that alleviates administrative tasks, freeing providers to focus on clinical care; a single-TIN medical group, which bolsters payer negotiations, facilitates clinical integration, and aligns financial incentives; an Accountable Care Organization (ACO) designed to engage patients, reduce inefficient utilization, and improve care coordination and patient quality metrics, thereby advancing value-based care; and a network connecting providers with new patient populations and enabling custom contracts with purchasers and payers. Founded in 2007, the company's headquarters are located in Arlington, Virginia. Privia Health Group, Inc. was formerly a subsidiary of Brighton Health Group Holdings, LLC.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 2,246 | 2,123 | 1,736 | 1,658 | 1,357 | 966 | 817 | 786 | 658 | |
| Cost of Goods Sold Incl. D&A | 2,031 | 1,913 | 1,560 | 1,496 | 1,222 | 903 | 734 | 718 | 601 | |
| Gross Profit | 216 | 209 | 177 | 162 | 135 | 64 | 83 | 68 | 56 | |
| Selling, General and Administrative Excl. Other | 49,734 | 165 | 153 | 134 | 149 | 279 | 55 | 51 | 53 | |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other Operating Expense | -49,555 | 10 | 7 | 7 | 5 | 2 | 2 | 1 | 1 | |
| Operating Income | 35 | 34 | 17 | 21 | -19 | -217 | 25 | 16 | 2 | |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 7 | 6 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 8 | 10 | 11 | 8 | 1 | 0 | 0 | 0 | 0 | |
| Net Income Before Taxes | 45 | 44 | 28 | 29 | -19 | -219 | 23 | 9 | -4 | |
| Income Taxes | 18 | 14 | 11 | 8 | -7 | -28 | -7 | 1 | 0 | |
| Consolidated Net Income | 22 | 23 | 14 | 23 | -9 | -188 | 31 | 8 | -3 | |
| Net Income From Continuing Operations | 28 | 30 | 17 | 21 | -12 | -191 | 31 | 8 | -4 | |
| Net Income | 22 | 23 | 14 | 23 | -9 | -188 | 31 | 8 | -3 | |
| EPS (Recurring) | 0.18 | 0.19 | 0.12 | 0.20 | -0.08 | -1.77 | 0.30 | 0.08 | -0.03 | |
| EPS (Basic, Before Extraordinaries) | 0.18 | 0.19 | 0.12 | 0.20 | -0.08 | -1.77 | 0.30 | 0.08 | -0.03 | |
| EPS (Diluted) | 0.17 | 0.18 | 0.11 | 0.19 | -0.08 | -1.77 | 0.30 | 0.08 | -0.03 | |
| EBITDA | 56 | 54 | 35 | 36 | -14 | -215 | 27 | 17 | 3 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 139.94 | 131.72 | 177.73 | 121.21 | — | — | — | — | — | |
| Price To Sales Ratio | 1.31 | 1.36 | 1.34 | 1.63 | 1.86 | 2.89 | — | — | — | |
| Gross Margin | 9.62 | 9.84 | 10.20 | 9.77 | 9.95 | 6.63 | 10.16 | 8.65 | 8.51 | |
| Operating Margin | 1.56 | 1.60 | 0.98 | 1.27 | -1.40 | -22.46 | 3.06 | 2.04 | 0.30 | |
| Net Margin | 0.98 | 1.08 | 0.81 | 1.39 | -0.66 | -19.46 | 3.79 | 1.02 | -0.46 | |
| Shares Outstanding | 124 | 122 | 119 | 117 | 111 | 108 | 106 | 106 | 103 | |
| Market Capitalization | 2,950 | 2,893 | 2,326 | 2,695 | 2,521 | 2,794 | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Mountcastle David | EVP & Chief Financial Officer | Jul 09 '26 | Sale | 27.67 | 21,275 | 588,679 | 164,853 | Jul 13 |
| Mountcastle David | EVP & Chief Financial Officer | Jul 07 '26 | Sale | 27.57 | 600 | 16,542 | 186,128 | Jul 09 |
| Morris Matthew Shawn | Director | Jul 06 '26 | Option Exercise | 2.00 | 53,722 | 107,444 | 130,373 | Jul 07 |
| Morris Matthew Shawn | Director | Jul 06 '26 | Sale | 27.24 | 53,722 | 1,463,387 | 68,188 | Jul 07 |
| Morris Matthew Shawn | Director | Jul 02 '26 | Sale | 27.33 | 59,037 | 1,613,481 | 76,651 | Jul 07 |
| Mountcastle David | EVP & Chief Financial Officer | Jul 02 '26 | Sale | 27.50 | 24,734 | 680,185 | 186,728 | Jul 07 |
| Morris Matthew Shawn | Director | Jul 02 '26 | Option Exercise | 2.00 | 59,037 | 118,074 | 135,688 | Jul 07 |
| Morris Matthew Shawn | Director | Jul 01 '26 | Sale | 26.70 | 82,675 | 2,207,728 | 76,651 | Jul 02 |
| Morris Matthew Shawn | Director | Jul 01 '26 | Option Exercise | 2.00 | 82,675 | 165,350 | 159,326 | Jul 02 |
| Morris Matthew Shawn | Director | Jun 30 '26 | Option Exercise | 2.00 | 52,823 | 105,646 | 129,474 | Jul 02 |
| Morris Matthew Shawn | Director | Jun 30 '26 | Sale | 25.72 | 52,823 | 1,358,608 | 76,651 | Jul 02 |
| Morris Matthew Shawn | Director | Jun 29 '26 | Sale | 25.33 | 63,212 | 1,601,160 | 76,651 | Jun 30 |
| Morris Matthew Shawn | Director | Jun 29 '26 | Option Exercise | 2.00 | 63,212 | 126,424 | 139,863 | Jun 30 |
| Mountcastle David | EVP & Chief Financial Officer | Jun 26 '26 | Option Exercise | 2.00 | 26,093 | 52,186 | 228,658 | Jun 30 |
| Mountcastle David | EVP & Chief Financial Officer | Jun 26 '26 | Sale | 25.18 | 17,196 | 432,995 | 211,462 | Jun 30 |